

Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for ibuprofen / pseudoephedrine, the scientific conclusions are as follows:

In view of available data on Kounis syndrome from the literature, and the established causal relationship between Kounis syndrome and ibuprofen the PRAC concluded that the product information of products containing ibuprofen/pseudoephedrine should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for ibuprofen / pseudoephedrine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing ibuprofen / pseudoephedrine is unchanged subject to the proposed changes to the product information

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

Section 4.4

A warning should be added as follows:

Cardiovascular and cerebrovascular effects

(...)

Cases of Kounis syndrome have been reported in patients treated with ibuprofen-containing products such as [product name]. Kounis syndrome has been defined as cardiovascular symptoms secondary to an allergic or hypersensitive reaction-associated with constriction of coronary arteries and potentially leading to myocardial infarction.

Section 4.8

The following adverse reaction should be added under the SOC Cardiac Disorders with a frequency not known:

Kounis syndrome

Package leaflet

Section 2, Warnings and precautions

What you need to know before you take [product]

Signs of an allergic reaction to this medicine, including breathing problems, swelling of the face and neck region (angioedema), chest pain have been reported with ibuprofen. Stop immediately [product name] and contact immediately your doctor or medical emergencies if you notice any of these signs.

Section 4, Possible side effects

Chest pain, which can be a sign of a potentially serious allergic reaction called Kounis syndrome

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	February 2024 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	7 April 2024
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	6 June 2024